OrthoPediatrics Corp. (NASDAQ:KIDS) CFO Sells $160,172.98 in Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) CFO Fred Hite sold 6,443 shares of OrthoPediatrics stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $160,172.98. Following the completion of the sale, the chief financial officer now owns 207,989 shares in the company, valued at $5,170,606.54. The trade was a 3.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

OrthoPediatrics Stock Up 1.6 %

Shares of NASDAQ KIDS opened at $25.54 on Friday. The firm has a market cap of $620.29 million, a PE ratio of -20.76 and a beta of 1.22. OrthoPediatrics Corp. has a 12-month low of $21.02 and a 12-month high of $35.99. The company’s fifty day simple moving average is $24.84 and its 200 day simple moving average is $25.53. The company has a quick ratio of 3.68, a current ratio of 7.17 and a debt-to-equity ratio of 0.19.

OrthoPediatrics (NASDAQ:KIDS) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. The firm had revenue of $52.67 million for the quarter, compared to analyst estimates of $51.16 million. During the same period last year, the firm earned ($0.23) earnings per share. As a group, sell-side analysts forecast that OrthoPediatrics Corp. will post -0.93 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on KIDS. Stifel Nicolaus reduced their target price on shares of OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, March 5th. Truist Financial dropped their price objective on shares of OrthoPediatrics from $28.00 to $25.00 and set a “hold” rating for the company in a research note on Wednesday, December 18th. Finally, Needham & Company LLC restated a “buy” rating and issued a $42.00 target price on shares of OrthoPediatrics in a research report on Wednesday, March 5th.

Hedge Funds Weigh In On OrthoPediatrics

Several hedge funds have recently bought and sold shares of KIDS. Millennium Management LLC bought a new stake in OrthoPediatrics during the fourth quarter valued at approximately $9,798,000. Point72 Asset Management L.P. bought a new stake in OrthoPediatrics during the 4th quarter valued at $7,450,000. Wasatch Advisors LP raised its holdings in OrthoPediatrics by 47.2% during the 4th quarter. Wasatch Advisors LP now owns 696,318 shares of the company’s stock valued at $16,141,000 after buying an additional 223,217 shares during the last quarter. Wellington Management Group LLP increased its position in OrthoPediatrics by 20.2% during the 4th quarter. Wellington Management Group LLP now owns 1,061,299 shares of the company’s stock valued at $24,601,000 after purchasing an additional 178,078 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in OrthoPediatrics by 29.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 671,968 shares of the company’s stock valued at $15,576,000 after purchasing an additional 152,681 shares during the period. Hedge funds and other institutional investors own 69.05% of the company’s stock.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.